BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Fate Therapeutics 

10931 North Torrey Pines Road
Suite 107
La Jolla  California  92037  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Fate Therapeutics (FATE) To Present At 14th Annual Needham Healthcare Conference 4/9/2015 6:08:08 AM
Fate Therapeutics (FATE) To Webcast Conference Call Reporting Fourth Quarter And Full Year 2014 Financial Results On March 12, 2015 3/6/2015 7:34:54 AM
Fate Therapeutics (FATE) Expands And Strengthens Leadership Team 3/3/2015 8:50:14 AM
Fate Therapeutics (FATE) To Present At Cowen and Company 35th Annual Health Care Conference 2/26/2015 8:17:44 AM
Fate Therapeutics (FATE) To Present At The 2015 Leerink Global Healthcare Conference 2/6/2015 8:16:08 AM
Fate Therapeutics (FATE) Announces Key 2015 Objectives For The Advancement Of Programmed Cellular Therapeutics Pipeline 1/12/2015 7:28:09 AM
Fate Therapeutics (FATE) To Present At Biotech Showcase 2015 1/6/2015 10:00:45 AM
Fate Therapeutics (FATE) Announces Interim Data From Ongoing Phase 2 PUMA Study 12/18/2014 7:39:28 AM
Fate Therapeutics (FATE) Highlights Effects Of Nutrient-Rich Media On Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood 12/9/2014 10:21:54 AM
Fate Therapeutics (FATE) Unveils Preclinical Findings Of Newly-Identified Small Molecule Modulator Combination For Ex Vivo Programming Of Mobilized Peripheral Blood 12/8/2014 7:29:55 AM
123456